DNA Aptamers for the Functionalisation of DNA Origami Nanostructures

Sakai, Yusuke; Islam, Md. Sirajul; Adamiak, Martyna; Shiu, Simon Chi‐Chin; Tanner, Julian A.; Heddle, Jonathan G.

doi:10.3390/genes9120571

Cited by 38 publications

(26 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[73] Thegeneral detection concepts introduced above can also be adapted for the detection of proteins and other biomarkers.T his usually requires the introduction of target-specific aptamers into the DN. [74] Detection of the bound analyte can then be achieved using AFM, [70,75] electrochemistry, [76] fluorimetry, [60] and CD spectroscopy, [77,78] and successful target detection was recently demonstrated even in whole blood. [76] Nevertheless,most of these works can be considered proof-ofprinciple studies that employed well-characterized aptamers with ah igh affinity toward some model targets such as thrombin, [75,78] ATP, [60,76] or adenosine.…”

Section: Diagnostic Applicationsmentioning

confidence: 99%

Challenges and Perspectives of DNA Nanostructures in Biomedicine

2020

View full text Add to dashboard Cite

DNA nanotechnology holds substantial promise for future biomedical engineering and the development of novel therapies and diagnostic assays. The subnanometer‐level addressability of DNA nanostructures allows for their precise and tailored modification with numerous chemical and biological entities, which makes them fit to serve as accurate diagnostic tools and multifunctional carriers for targeted drug delivery. The absolute control over shape, size, and function enables the fabrication of tailored and dynamic devices, such as DNA nanorobots that can execute programmed tasks and react to various external stimuli. Even though several studies have demonstrated the successful operation of various biomedical DNA nanostructures both in vitro and in vivo, major obstacles remain on the path to real‐world applications of DNA‐based nanomedicine. Here, we summarize the current status of the field and the main implementations of biomedical DNA nanostructures. In particular, we focus on open challenges and untackled issues and discuss possible solutions.

show abstract

Section: Diagnostic Applicationsmentioning

confidence: 99%

Challenges and Perspectives of DNA Nanostructures in Biomedicine

2020

View full text Add to dashboard Cite

show abstract

“…(B) DNA aptamers positioned on DNA origami for various applications (diagnosis, engineering dynamic structures, or binding cells surface). Reprinted with permission under a Creative Commons Attribution 4.0 International (CC BY 4.0) License from ref . Copyright 2018 MDPI.…”

Section: Challenges With Delivery and Cellular Uptakementioning

confidence: 99%

DNA Nanostructures: Current Challenges and Opportunities for Cellular Delivery

2021

View full text Add to dashboard Cite

DNA nanotechnology has produced a wide range of self-assembled structures, offering unmatched possibilities in terms of structural design. Because of their programmable assembly and precise control of size, shape, and function, DNA particles can be used for numerous biological applications, including imaging, sensing, and drug delivery. While the biocompatibility, programmability, and ease of synthesis of nucleic acids have rapidly made them attractive building blocks, many challenges remain to be addressed before using them in biological conditions. Enzymatic hydrolysis, low cellular uptake, immune cell recognition and degradation, and unclear biodistribution profiles are yet to be solved. Rigorous methodologies are needed to study, understand, and control the fate of self-assembled DNA structures in physiological conditions. In this review, we describe the current challenges faced by the field as well as recent successes, highlighting the potential to solve biology problems or develop smart drug delivery tools. We then propose an outlook to drive the translation of DNA constructs toward preclinical design. We particularly believe that a detailed understanding of the fate of DNA nanostructures within living organisms, achieved through thorough characterization, is the next required step to reach clinical maturity.

show abstract

“…To achieve broad‐spectrum efficacy, up to ten streptavidin proteins were used as a multivalent anchor points on biotinylated staple strands integrated into “windows” of the DNA origami structure, and as many as three biotinylated lysozymes were attached to each of these anchor points (see Figure 6c). The edges of the sheet‐like DNA origami surface were decorated with 14 aptamers known to target E. coli and B. subtilis strains, [ 116 ] and a dye molecule was also included for detection. The compound DNA origami construct did lead to a significantly amplified inhibitory effect when applied to the Gram‐positive B. subtilis , with an aggregate amount of 300 nM of lysozyme on the structures causing a significant reduction in growth over 16 h compared with relatively little effect from an equivalent amount of free enzyme.…”

Section: Dna Nanostructures For Pathogen Inhibitionmentioning

confidence: 99%

DNA Nanostructures in the Fight Against Infectious Diseases

Smith

Keller

2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

The ongoing COVID-19 pandemic has once more led to the realization that humanity is dangerously ill prepared for fighting the threats associated with epidemic outbreaks of infectious diseases. COVID-19 is only the latest in a long list of viral diseases, including SARS, [1] MERS, [2] Zika, [3] Ebola, [4] and Nipah, [5] that emerged as severe threats to public health in the past two decades and that continue to threaten human lives. However, also diseases that have plagued humanity for centuries still present a severe burden. For instance, the 20th century has seen three influenza pandemics with death tolls in the millions [6] and the seasonal flu still kills on average an estimated 389 000 people each year. [7] Furthermore, due to the global rise of antibiotic resistance in the past few decades, bacterial infections have once again become a severe threat to human health. [8] In 2015, about 670 000 patients in the EU alone suffered from infections with antibiotic-resistant strains of eight bacterial pathogens, resulting in 33 000 deaths. [9] The situation in the US is similar, with an estimated 23 000 deaths each year as a direct result of more than 2 million multidrug-resistant infections. [10] In low-and middle-income countries with limited ability to pay for second-line drugs, antibiotic resistance results in even higher mortality rates. In 2010, about 38 000 deaths in Thailand alone were attributed to infections with only five antibiotic-resistant bacteria. [11] In India, it is estimated that about 60 000 neonatal deaths each year result from antibiotic-resistant bacterial infections. [8] More recently, the worldwide emergence of antifungal resistance has raised grave concerns as well, [12] as invasive fungal infections are responsible for at least 2 million life-threatening

show abstract

DNA Aptamers for the Functionalisation of DNA Origami Nanostructures

Cited by 38 publications

References 123 publications

Challenges and Perspectives of DNA Nanostructures in Biomedicine

Challenges and Perspectives of DNA Nanostructures in Biomedicine

DNA Nanostructures: Current Challenges and Opportunities for Cellular Delivery

DNA Nanostructures in the Fight Against Infectious Diseases

Contact Info

Product

Resources

About